All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Vima banks $100m in Series A to progress Parkinson’s drug

Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill,…
FDA issues warning to Novo Nordisk on unreported semaglutide safety events

Novo Nordisk has received a warning letter from the US Food and Drug Administration (FDA) related to the company’s failure…
UK health authorities join forces to champion foreign infectious disease trials

Health divisions within the UK government and British non-profit organisations have banded together to support infectious disease trials in Africa,…
FDA homes in on biosimilar accessibility in new draft guidance

The US Food and Drug Administration (FDA) has further updated its regulatory framework around biosimilar medicines in a bid to…
Vinay Prasad to leave the FDA again

Vinay Prasad is once again set to depart from his role at the US Food and Drug Administration (FDA), after…

Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal

Alnylam Pharmaceuticals has forged a discovery collaboration worth up to $1.23bn with cardiovascular disease specialist, Tenaya Therapeutics. Through this partnership,…
Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit

Moderna has agreed to pay up to $2.25bn to settle a patent infringement lawsuit with Genevant and Arbutus, ending a…
Targeted therapies to join chemo as oncology treatment backbone

In recent years, the oncology sector has undergone a fundamental shift away from chemotherapy-dominant treatment towards the use of regimens…
Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal

Sanofi has taken a chance on Sino Biopharmaceutical’s first-in-class, anti-inflammatory and anti-fibrotic asset, rovadicitinib, through a licensing agreement worth up…
OSE narrows pipeline focus amid Boehringer MASH collaboration retreat

French biotech OSE Therapeutics has shifted focus to its later-stage clinical assets as it looks to prioritise near-term value creation.…